Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
Immune checkpoint inhibitors, including those targeting CTLA-4/B7 and PD-1/PD-L1 inhibitory pathways, are now available for clinical use on cancer patients. Other interesting checkpoint inhibitors are currently under the development. CD47 is a protein broadly expressed on the surface of normal cells...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2018-08-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2018.18.0217.htm |